Field Medical has appointed a new Chief Executive Officer, Mark A. Turco, MD, to spearhead the company’s growth into the next phase of healthcare innovation. This is a clear indicator of the company’s commitment to the advancement of medical technology. Dr. Turco is a renowned figure with decades of experience in cardiovascular devices and clinical research. He is dedicated to spearheading the strategy and operations of Field Medical. Additionally, Dr. Turco is committed to accelerating the company’s products and innovation. Dr. Turco has previously held leadership roles in other renowned companies in the medtech industry. Therefore, it is clear that Dr. Turco is a great addition to Field Medical, a company operating in a competitive industry. The company is dedicated to growing in the advanced medical technology industry.
“Mark’s unique background as a cardiologist, clinical trialist and an experienced medical device executive equips him well to guide Field Medical through this next phase of growth,” said Ben Cannon, board member of Field Medical and member of the BioStar Capital and Cue Growth investment teams. “As we accelerate our clinical programs and strengthen our operational capabilities, his executive experience in advancing complex medical technologies across development, regulatory and commercialization milestones will enable disciplined execution and sustainable long-term value creation.”
Strengthening Innovation and Clinical Leadership
In addition, the company continues to focus on patient-centered innovation and clinical excellence. The leadership transition is consistent with the organization’s long-term mission to deliver improved healthcare outcomes. Moreover, the company is also planning to capitalize on Dr. Turco’s knowledge to enhance its research and development initiatives. This is a major milestone in Field Medical’s quest for leadership in healthcare innovation.
“I am honored to join Field Medical at this pivotal moment in its evolution,” said Dr. Turco. “The company has built a differentiated PFA platform with the potential to meaningfully address significant unmet patient needs in both ventricular arrhythmias and atrial fibrillation. I look forward to partnering closely with the exceptional Field Medical team to rigorously advance our clinical programs and navigate regulatory pathways to meet our operational goals.”
For more stories on technology leaders shaping the future of enterprise solutions, visit our CXO Insiders.
Source: PRNewswire
